Common blood pressure medicine blocks molecule that can trigger the disease
A drug commonly used to control high blood pressure may also help prevent the onset of Type 1 diabetes in up to 60 percent of those at risk for the disease, according to researchers at the University of Colorado Anschutz Medical Campus and the University of Florida (UF) in Gainesville.
The study was published online this week in the Journal of Clinical Investigation.
“This is the first personalized treatment for Type 1 diabetes prevention,” said Aaron Michels, MD, a researcher at the Barbara Davis Center for Childhood Diabetes and associate professor of medicine at CU Anschutz. “We made this discovery using a supercomputer, on the lab bench, in mice and in humans.”
The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children. It is on the World Health Organization’s list of essential drugs.
But like many drugs used for one condition, Michels and his colleagues found it useful for something totally unrelated.
Some 60 percent of people at risk of getting Type 1 diabetes possess the DQ8 molecule which significantly increases the chance of getting the disease. The researchers believed that if they could block specifically the DQ8 molecule they could also block the onset of the disease.
“All drugs have off-target effects. If you take too much acetaminophen you can hurt your liver,” Michels said. “We took every FDA-approved small molecule drug and analyzed HLA-DQ8 binding through a supercomputer. We searched a thousand orientations for each drug to identify those that would fit within the DQ8 molecule binding groove.”
After running thousands of drugs through the supercomputer, they found that methyldopa not only blocked DQ8, but it didn’t harm the immune function of other cells like many immunosuppressant drugs do.
The research spanned 10 years and its efficacy was shown in mice and in 20 Type 1 diabetes patients who took part in a clinical trial at the Barbara Davis Center at the University of Colorado School of Medicine.
“We can now predict with almost 100 percent accuracy who is likely to get Type 1 diabetes,” Michels said. “The goal with this drug is to delay or prevent the onset of the disease among those at risk.”
The drug is taken orally, three times a day.
Implications for treatment
Michels and UF Health researcher David Ostrov, PhD, hope this same approach of blocking specific molecules can be used in other diseases.
“This study has significant implications for treatment of diabetes and also other autoimmune diseases,” said Ostrov, associate professor of pathology, immunology and laboratory medicine in the UF College of Medicine and a member of the UF Health Cancer Center, Genetics Institute and Center for NeuroGenetics. “This study suggests that the same approach may be adapted to prevent autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others.”
The next step will be a larger clinical trial sponsored by the National Institutes of Health in spring.
“With this drug, we can potentially prevent up to 60 percent of Type 1 diabetes in those at risk for the disease,” Michels said. “This is very significant development.”
The Latest on: Type 1 diabetes
Type 1 Connection Diabetes Support Group offered by MCHS–Red Cedar
on March 14, 2018 at 7:53 pm
The inaugural Type 1 Connection Diabetes Support Group will be held on Tuesday, April 3, from 4–5 p.m. in the East Conference Room at Mayo Clinic Health System–Red Cedar (2321 Stout Road, Menomonie). Thereafter, the group will meet at the same time on ... […]
Moved By Tragic Diabetes Story, Fellow Type 1, Bret Michaels, Looks To Insulin Resolution
on March 14, 2018 at 10:30 am
CALABASAS, Calif., March 14, 2018 /PRNewswire/ -- The following is a statement from Bret Michaels provided by Michaels Entertainment Group in response to a recent story. As an individual living with Type 1 diabetes since the age of 6, the story of Alec ... […]
Medtronic makes further moves into Type 2 diabetes with FDA approval of new CGM sensor
on March 13, 2018 at 8:32 pm
Medtronic dominates the insulin pump market, which is largely targeted toward type 1 diabetes patients. Now with the introduction of a smart CGM for patients who inject insulin, the next step will be for the company to persuade them to ditch the injection ... […]
Type 1 diabetes: Does the gut hold the key to prevention?
on March 13, 2018 at 5:20 pm
Targeting specific microbiota in the gut could be one way to protect against type 1 diabetes, a new study concludes. Researchers from the University of Queensland in Australia have found distinct gut microbiota alterations in rodents and humans that are at ... […]
Batavia mom is raising awareness for Type 1 diabetes
on March 12, 2018 at 9:18 am
Joan Benedetto of Batavia is finding powers within herself she never knew she had. Ever since her son, Jayce, was diagnosed with Type 1 diabetes, she has become a tireless advocate -- and not just to raise awareness. In part, because of her activism, more ... […]
Enlisting Gut Bacteria And Fiber To Fight Diabetes
on March 9, 2018 at 9:41 am
About 1 in 11 Americans has diabetes. Type 2 diabetes is the most common form and is on the rise in the U.S. in both children and adults. For the study, a team of scientists in China put 27 people with type 2 diabetes on a very high-fiber diet and followed ... […]
Lilly Extends Diabetes Research Collaboration
on March 9, 2018 at 6:57 am
Eli Lilly and Co. (NYSE: LLY) will continue its fight against type 1 diabetes with the European Foundation for the Study of Diabetes and the Juvenile Diabetes Research Foundation. The entities have announced a research collaboration, that started in 2015 ... […]
via Google News and Bing News